The role of Bcl-2 family proteins in chronic lymphocytic leukaemia

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 837-842

  Buggins, Andrea G S ^a   Pepper, Chris J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Chronic lymphocytic leukaemia; Drug resistance; Microenvironment; Therapeutics

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; FLUDARABINE; ISOSORBIDE; OBATOCLAX; OBLIMERSEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; T W 37; TW 37; UNCLASSIFIED DRUG; WL 276;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC EPIGENESIS; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MEMBRANE PERMEABILITY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MITOCHONDRIAL MEMBRANES; MODELS, BIOLOGICAL; MULTIGENE FAMILY; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES;

EID: 77952952903     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.011     Document Type: Review

References (88)

1. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
2. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992, 148:2207-2216.
3. Tsujimoto Y., Cossman J., Jaffe E., Croce C. Involvement of the Bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443.
4. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442.
5. Tsujimoto Y., Croce C. Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986, 83:5214-5218.
6. Reed J.C., Cuddy M., Slabiak T., Croce C.M., Nowell P.C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988, 336:259-261.
7. Tsujimoto Y. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 1989, 11:1331-1336.
8. Reed J.C., Stein C., Subasinghe C., et al. Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990, 50:6565-6570.
9. Kroemer G. Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 2003, 304:433-435.
10. Choi C., Benveniste E.N. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004, 44:65-81.
11. Acehan D., Jiang X., Morgan D.G., et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002, 9:423-432.
12. Hockenbery D.M., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
13. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
14. Yang J., Liu X., Bhalla K., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275:1129-1132.
15. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
16. Lee J.S., Dixon D.O., Kantarjian H.M., Keating M.J., Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987, 69:929-936.
17. Messmer B.T., Messmer D., Allen S.L., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
18. Ghia P., Granziero L., Chilosi M., Caligaris-Cappio F., Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002, 12:149-155.
19. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003, 123:380-388.
20. Munk-Pedersen I., Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004, 45:2365-2372.
21. Ghia P., Circosta P., Scielzo C., et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005, 294:135-145.
22. Schena M., Gottardi D., Ghia P., et al. The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymphoma 1993, 11:173-179.
23. Reed J.C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 1996, 72-100.
24. Faderl S., Keating M.J., Do K.A., et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002, 16:1045-1052.
25. Pepper C., Hoy T., Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997, 76:935-938.
26. Pepper C., Hoy T., Bentley P., Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998, 28:355-361.
27. Kitada S., Andersen J., Akar S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998, 91:3379-3389.
28. Hanada M., Delia D., Aiello A., Stadtmauer E. Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
29. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
30. Calin G.A., Ferracin M., Cimmino A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
31. Miyashita T., Krajewski S., Krajewska M., et al. Tumor suppressor p53 is a regulator of BCL-2 and BAX in gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
32. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of human Bax gene. Cell 1995, 80:293-299.
33. Yu J., Wang Z., Kinzler K.W., Vogelstein B., Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003, 100:1931-1936.
34. Oda E., Ohki R., Murasawa H., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
35. Sax J.K., Fei P., Murphy M.E., et al. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002, 4:842-849.
36. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
37. Tam C.S., Shanafelt T.D., Wierda W.G., et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M.D. Anderson and Mayo Clinic experience. Blood 2009, 114:957-964.
38. Chipuk J.E., Kuwana T., Bouchier-Hayes L., et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
39. Deng X., Gao F., Flagg T., Anderson J., May W.S. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol 2006, 26:4421-4434.
40. McConkey D.J., Chandra J., Wright S., et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996, 156:2624-2630.
41. Thomas A., El Rouby S., Reed J.C., et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
42. Robertson L.E., Plunkett W., McConnell K., Keating M.J., McDonnell T.J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996, 10:456-459.
43. Pepper C., Thomas A., Hoy T., Bentley P. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol 1999, 104:581-588.
44. Starczynski J., Pepper C., Pratt G., et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J Clin Oncol 2005, 23:1514-1521.
45. Pedersen I.M., Kitada S., Leoni L.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
46. Longo P.G., Laurenti L., Gobessi S., et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
47. Bannerji R., Kitada S., Flinn I.W., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003, 21:1466-1471.
48. Hussain S.R., Cheney C.M., Johnson A.J., et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007, 13:2144-2150.
49. Pepper C., Lin T.T., Pratt G., et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukaemia and is associated with other poor prognostic markers. Blood 2008, 112:3807-3817.
50. Derenne S., Monia B., Dean N.M., et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199.
51. Michels J., O'Neill J.W., Dallman C.L., et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004, 23:4818-4827.
52. Osorio L.M., De S.A., Aguilar-Santelises M., Mellstedt H., Jondal M. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 1997, 89:2833-2841.
53. Molica S., Dattilo A., Giulino C., Levato D., Levato L. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica 1998, 83:1122-1124.
54. Willis S.N., Fletcher J.I., Kaufmann T., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
55. Letai A., Bassik M.C., Walensky L.D., et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
56. Certo M., Del Gaizo Moore V., Nishino M., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
57. Chen L., Willis S.N., Wei A., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005, 17:393-403.
58. Mackus W.J., Kater A.P., Grummels A., et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005, 19:427-434.
59. Burger M., Hartmann T., Krome M., et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005, 106:1824-1830.
60. Burger J.A., Tsukada N., Burger M., et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell derived factor-1. Blood 2000, 96:2655-2663.
61. Nishio M., Endo T., Tsukada N., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106:1012-1020.
62. Smit L.A., Hallaert D.Y., Spijker R., et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007, 109:1660-1668.
63. Hallaert D.Y., Spijker R., Jak M., et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007, 14:1958-1967.
64. Vogler M., Butterworth M., Majid A., et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113:4403-4413.
65. Willimott S., Baou M., Naresh K., Wagner S.D. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007, 138:721-732.
66. Petlickovski A., Laurenti L., Li X., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105:4820-4827.
67. Ruiz-Vela A., Aggarwal M., de la Cueva P., et al. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. Blood 2008, 111:1665-1676.
68. Lagneaux L., Delforge A., Bron D., De Bruyn C., Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91:2387-2396.
69. Jurlander J. The cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1998, 27:29-52.
70. Seiffert M., Stilgenbauer S., Dohner H., Lichter P. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007, 21:1977-1983.
71. Lee Y.K., Bone N.D., Strege A.K., Shanafelt T.D., Jelinek D.F., Kay N.E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004, 104:788-794.
72. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
73. Wang L., Sloper D.T., Addo S.N., Tian D., Slaton J.W., Xing C. WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res 2008, 68:4377-4383.
74. Wang Z., Song W., Aboukameel A., et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008, 123:958-966.
75. Balakrishnan K., Wierda W.G., Keating M.J., Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008, 112:1971-1980.
76. Balakrishnan K., Burger J.A., Wierda W.G., Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediatedMcl-1 induction and drug resistance. Blood 2009, 113:149-153.
77. Campas C., Cosialls A.M., Barragan M., et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 2006, 34:1663-1669.
78. Dorai T., Goluboff E.T., Olsson C.A., Buttyan R. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997, 17:3307-3312.
79. Luzi E., Papucci L., Schiavone N., et al. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther 2003, 10:201-208.
80. O'Brien S., Moore J.O., Boyd T.E., et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009, 27:5208-5212.
81. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997, 349:1137-1141.
82. Pepper C., Hooper K., Thomas A., Hoy T., Bentley P. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 2001, 42:491-498.
83. Lin Y., Choksi S., Shen H.M., et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 2004, 279:10822-10828.
84. Elbashir S.M., Harborth J., Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
85. Han Y.H., Cao X., Lin B., et al. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 2006, 25:2974-2986.
86. Yip K.W., Godoi P.H., Zhai D., et al. A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule bcl-b inhibitors. J Biomol Screen 2008, 13:665-673.
87. Kolluri S.K., Zhu X., Zhou X., et al. A short Nur77 peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008, 14:285-298.
88. Ferlini C., Cicchillitti L., Raspaglio G., et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009, 69:6906-6914.